临床荟萃

• 荟萃分析 • 上一篇    下一篇

二甲双胍与胰腺癌患者生存期Meta分析

  

  1. 昆明医科大学第六附属医院 肝胆外科,云南 昆明 653100
  • 出版日期:2017-11-05 发布日期:2017-11-20
  • 通讯作者: 通信作者:李礼, Email:li_li_6668@163.com

Metformin and overall survival benefit in pancreatic cancer patients: a meta analysis

  1. Department of Hepatobiliary Surgery, the Sixth Affiliated Hospital of Kunming Medical University, Yuxi 653100,  China
  • Online:2017-11-05 Published:2017-11-20
  • Contact: Corresponding author: Li Li, Email:li_li_6668@163.com

摘要: 目的  系统评价二甲双胍对胰腺癌患者总生存期的影响。方法 检索EMBase、PubMed数据库,检索日期限定为建库至2017年6月。由2名作者独立对文献进行筛选、数据提取及文献质量评估。以NewcastleOttawa scale(NOS)评分法评估文献质量,≥6分为高质量文献。结果 共纳入11篇文献。荟萃分析显示:与非二甲双胍治疗相比,二甲双胍治疗能提高胰腺癌患者总生存期(OS)(HR=0.85; 95%CI=0.75~0.95,P=0.006),在亚组分析中的亚洲国家和高质量的文章中也得到了这种结果。结论 与非二甲双胍治疗相比,二甲双胍治疗能提高胰腺癌患者的总生存期。

关键词: 胰腺肿瘤, 二甲双胍, 总生存期, meta分析

Abstract: Objective  To evaluate the effect of metformin on the overall survival of pancreatic cancer patients. Methods  A systematic search was conducted  in the  published literature on studies on the association between  metformin and overall survival benefit in pancreatic cancer patients up to June 2017 from EMBase and PubMed. The identified articles were reviewed for additional references. The most adjusted risk estimates were extracted by two authors and summarized using random effects metaanalysis. The quality of the study was assessed by the NewcastleOttawa Scale (NOS), and the study with score ≥6 was taken as the highquality study.Results  Eleven articles were included.The metaanalysis showed that  metformin treatment  can  increase the overall survival  (OS) of patients with pancreatic cancer compared with nonmetformin treatment (HR=0.85,95%CI=0.750.95,P=0.006),and in subgroup analysis Asian countries and high quality articles also supported  this results. Conclusion  Metformin increased  the overall survival of pancreatic cancer patients compared with nonmetformin treatment.

Key words: pancreatic neoplasms;metformin, overall survival, meta analysis